Healthcare Industry News: S.A.
News Release - March 4, 2010
IVAX Diagnostics' Diamedix Subsidiary Signs Three Year Exclusive Distribution Agreement with Fumouze Diagnostics
Increases European Footprint To Include FranceMIAMI--(HSMN NewsFeed)--IVAX Diagnostics, Inc. (AMEX: IVD ), a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, purS.A.t to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.’s suite of diagnostic tests in France. Diamedix iS.A.U.S. subsidiary of IVAX DiagnosticS.A.d Delta Biologicals is IVAX Diagnostics’ subsidiary located in Italy. The initial term of the distribution agreement is three years.
Fumouze Diagnostics has been a major participant in the diagnostics field for more than 40 years, and offerS.A.broad range of products to its private and public laboratory clients. To support the sales efforts in France under this distribution agreement, Fumouze Diagnostics haS.A.reed to hire a sales representative to sell Diamedix and Delta Biologicals’ products in collaboration with Fumouze Diagnostics’ existing direct sales force. Diamedix and Delta Biologicals have a combined suite of products that includes more than 200 diagnostics tests in the areas of infectious diS.A.e, autoimmune diS.A.e and allergies. Delta BiologicalS.A.so manufactureS.A.line of instruments for use in clinical and hospital laboratories.
Charles Struby, Ph.D., Chief Executive Officer and President of IVAX Diagnostics, said, “As the international market for diagnostics increases in importance, one of our goals for 2010 is to increase our presence in key countries in Europe and South America. We expect that our distribution agreement with Fumouze Diagnostics will open the French market to Diamedix and Delta Biologicals’ suite of more than 200 diagnostic testS.A.d will be a major step towardS.A.taining our goal of expanding our product reach in Europe. We believe that partnering with Fumouze Diagnostics, a company with a well-eS.A.lished history of bringing important products to market, and a reputation for outS.A.ding customer service, will provide us with a strong and well-eS.A.lished distribution network for our expanding suite of diagnostics products.”
About Fumouze Diagnostics
Fumouze Diagnostics (www.fumouze.com) has been well eS.A.lished in the field of medical biology for over 40 years. Its top priority is to offer its clientS.A.high-quality service and innovative as well as performing products. Specialists in rapid testing, Fumouze Diagnostics offerS.A.broad range of products to private and public laboratories. It specializes mostly in parasitology, mycology, virology, biochemistry and immunochemistry. Fumouze Diagnostics regularly launches new products developed either from its own reS.A.ch or from international companies. Fumouze Diagnostics exports to numerous countries: in Europe, the Far and Middle East, Africa and OverS.A. Departments.
About IVAX Diagnostics, Inc.
IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered in Miami, Florida, iS.A.fully integrated in vitro diagnostics company that develops, manufactureS.A.d distributes in the United S.A.eS.A.d internationally, proprietary diagnostic reagents, test kitS.A.d instrumentation, primarily for autoimmune and infectious diS.A.es, through its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc.
Safe Harbor S.A.ement
Except for the historical matters contained herein, S.A.ements in this press release are forward-looking and are made purS.A.t to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. InvestorS.A.e cautioned that forward-looking S.A.ements involve riskS.A.d uncertainties that may affect the businesS.A.d prospects of IVAX Diagnostics, Inc., including, without limitation: the riskS.A.d uncertaintieS.A.sociated with Diamedix Corporation’s distribution agreement with Fumouze Diagnostics, including, without limitation, that it may not successfully assist IVAX Diagnostics or its subsidiaries in its goal of increasing its presence and expanding its product reach in Europe, provide IVAX Diagnostics or its subsidiaries with a distribution network for its suite of diagnostic products or otherwise achieve its intended results or positively impact IVAX Diagnostics’ financial condition or operating results; and other riskS.A.d uncertainties that may cause results to differ materially from those set forth in the forward-looking S.A.ements. In addition to the riskS.A.d uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other riskS.A.d uncertainties discussed in IVAX Diagnostics’ filings with the SecuritieS.A.d Exchange Commission, including, without limitation, the riskS.A.d uncertainties discussed under the heading “Risk Factors” in such filings.
Source: IVAX Diagnostics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!